Amid growing demand for portable, low-cost diagnostics, Indian startup Swasthya Slate is developing a device that could help reduce costs and improve outcomes for patients in developing countries.
It's been a long road for Shan5, the low-cost pentavalent from Sanofi-owned Shantha Biotechnics. Now, after manufacturing tie-ups four years ago cost the company a $340 million contract to supply the vaccine, it's finally rolling out the product in India.
How bad can an FDA ban on plants be when the U.S. is your primary market? Really bad, India's Wockhardt found out this quarter, with its profit dropping more than $22 million, a 97% freefall.
Prime Minister Narendra Modi got an ear full from both constituents and the U.S. drug industry about India's approach to drug patents during his first visit to the U.S. last month. Three weeks later, there is evidence the government will take a considered approach to the contested issue.
Some Indian companies that had put off production of HIV/AIDS meds while they waited for the government to sign contracts are now having to seriously ramp up because of shortages of some meds, Reuters reports.
Indian drugmaker IPCA, which has stopped shipping products to the U.S. and Canada from a plant in Bangalore, has acquired a high potency oral solid dosage facility from Alpa Laboratories.
Over the past year India has begun to face up to the reality that its regulatory machinery is insufficient to enforce quality standards, leading authorities to commit to hiring more inspectors. Now those new inspectors are tagging along on inspections run by their international peers.
As Indian Prime Minister Narendra Modi travels to the U.S. to meet with officials, Doctors Without Borders (MSF) has one message for him: Don't back down on drug patents.
The Indian government has begun legal action against think tank the American Enterprise Institute (AEI) over a paper on drug quality, The Times of India reports.
The three-way spat between Health Canada, local media and Apotex is rumbling on. Late last week Health Canada won an equivocal thumbs-up from the media for its move to quarantine products from one of Apotex's Indian plants, only for the generic drugmaker to hit back with a press release to "set the record straight."